Prebiotics and Allergy: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Nutrition & Dietetics
Contributor:
Carole Brosseau
,
Amandine Selle
,
Debra J. Palmer
,
Susan L. Prescott
,
Sébastien Barbarot
,
Marie Bodinier

Allergic diseases now affect over 30% of individuals in many communities, particularly young children, underscoring the need for effective prevention strategies in early life. These allergic conditions have been linked to environmental and lifestyle changes driving the dysfunction of three interdependent biological systems: microbiota, epithelial barrier and immune system. While this is multifactorial, dietary changes are of particular interest in the altered establishment and maturation of the microbiome, including the associated profile of metabolites that modulate immune development and barrier function. Prebiotics are non-digestible food ingredients that beneficially influence the health of the host by 1) acting as a fermentable substrate for some specific commensal host bacteria leading to the release of short-chain fatty acids in the gut intestinal tract influencing many molecular and cellular processes; 2) acting directly on several compartments and specifically on different patterns of cells (epithelial and immune cells). Nutrients with prebiotic properties are therefore of central interest in allergy prevention for their potential to promote a more tolerogenic environment through these multiple pathways. 

  • prebiotics
  • mechanisms
  • allergy
  • microbiota
  • immune system
  • epithelial barrier

1. Introduction

Allergic diseases (atopic dermatitis (AD), respiratory allergies and food allergies (FA)) are a mounting public health burden—now classified as the 4th most common global disease by the World Health Organization. Affecting up to 30% of the world population [1][2], allergic diseases are also the earliest onset non communicable diseases (NCDs) and a clear manifestation of the vulnerability of the immune system (IS) to modern environmental changes.
The development of allergic diseases has been linked to dysfunction of complex mucosal systems, which collectively comprise of the microbiota, the epithelial barrier and the IS—operating as an interdependent functional unit to maintain both host protection and immune tolerance. In an allergic state, these processes are disrupted, most notably with the failure of immune tolerance, albeit to specific allergen targets. The reasons for this specificity are still unclear, but generally associated with alternations in the T regulatory cell (Treg) and T helper (Th) cell function. The resultant shift in a Th1/Th2 cytokine balance towards a Th2 dominance is associated with the overproduction of interleukine 4 (IL-4), and allergen specific immunoglobuline E (IgE) [3].
There are now numerous studies showing altered microbial signatures in infants who subsequently develop allergic diseases [4][5][6][7][8][9][10], including studies suggesting a critical window during which these alterations may be a specific risk factor for later allergic diseases. This provides a plausible causal pathway for allergy pathogenesis. There are numerous environmental changes that may be contributing to changes in human microbiota profiles. These include dietary changes [11], especially more ultra-processed foods and reduced fiber and fermentable foods consumption, reduced fresh foods and natural microbial loads in our food supply, widespread use of antibiotics and antimicrobial products in healthcare, environmental toxicants, and reduced contact with biodiversity and natural environments.
Pre-symptomatic changes in the immune function have been detected at birth in children who develop a subsequent allergic disease [1][6][12][13], also suggesting that the impact of environmental change is occurring very early in development—also reflected in the early onset of conditions such as AD and FA, often within the first months of life [14]. Again, this underscores the importance of very early interventions to prevent allergic diseases. Indeed, it is already well-documented that an exposure to a range of environmental factors during pregnancy, delivery and lactation, have the capacity to influence the immune development of the fetus and newborn [15][16]. More recently, this has been shown to include the transfer of bacteria and immune factors from the mother to the fetus or child [6][7] all with the capacity to influence the establishment of both microbiota and the IS. This is the basis for current studies specifically focusing on dietary nutrients known to modulate the microbiome during these critical periods—namely prebiotics. Indeed, both human studies and experimental animal models show that consumption of prebiotics by the mother and her offspring appears to influence the development of both the microbiota and IS.

2. Prebiotics

2.1. First Generation of Prebiotics

Prebiotics were first described by Gibson and Roberfroid in 1995 as “non-digestible food ingredients that beneficially influence the health of the host by stimulating the activity of one or more commensal colon bacteria” [17]. The acquisition of new scientific data on their mode of action and their specificity allowed refining of this definition to being requalified in 2017, by the International Scientific Association of Probiotics and Prebiotics (ISAPP), as “substrates selectively used by micro-organisms of the host conferring benefits for his health”. Prebiotics must meet three criteria: 1: Be resistant to digestion in the stomach and upper intestine, 2: Be fermentable by the gut microbiota and 3: Specifically stimulate the growth and/or activity of intestinal bacteria beneficial to our health [18]. The benefits of prebiotics are not limited to the gut, they can also act systemically [19]. Indeed, new original studies demonstrate that prebiotics can also modulate IS and facilitate many biologic processes, including infection prevention and the improvement of mood and memory [19].
Prebiotics are usually composed of linked sugars such as oligosaccharides and short-chain polysaccharides (see Figure 1). These molecules have the chemical characteristic of being indigestible by the enzymes present in the intestinal tract. They will therefore be able to serve as nutritional substrates for microorganisms considered “beneficial” such as Bifidobacterium and Bacteroides or come into direct contact with the surrounding cells [20]. Fructans such as fructo-oligosaccharides (FOS) and inulin, as well as galactans such as galacto-oligosaccharides (GOS) are the most studied prebiotics for their modulatory effects on the microbiota. The prebiotics that are most commonly found to occur naturally in our foods are the FOS and inulin. They are found in plant-based foods such as in some vegetables (leek, onion, garlic, artichoke, chicory and asparagus), fruits (banana) and cereals (rye, corn). With a balanced European diet, 3–11 g of natural prebiotics can be consumed per day [21]. In comparison, only 1–4 g is usually consumed daily in the USA. Prebiotics are also produced commercially as supplements through the hydrolysis of polysaccharides or enzymatic reactions from lower molecular weight sugars. Although there are many commercially available foods and food ingredients that claim to be prebiotics, currently only lactulose, FOS and GOS have a proven prebiotic effect and status.
Figure 1. Chemical structures of the first generation of prebiotics. FOS: Fructo-oligosaccharides, GlOS: Gluco-oligosaccharides, GOS: Galacto-oligosaccharides, HMO: Human milk oligosaccharides, IMO: Isomalto-oligosaccharids [22].

2.2. Second Generation of Prebiotics

A second generation of prebiotics was designed in the 2000s to improve their functionality. The strategy consisted of adapting the chemical structure of prebiotics by a digestion with a specific enzyme produced by a probiotic. The prebiotic Bimuno (Clasado Biosciences Ltd.) is a good example. It corresponds to a GOS mixture produced from lactose using enzymes from the probiotic Bifidobacterium bifidum NCIMB 41171. It has:
-a highly selective and powerful prebiotic effect (growth of beneficial Bifidobacterium and improved colonization resistance) [23]. It has been demonstrated to be effective as a prebiotic in healthy adults, healthy elderly adults, irritable bowel syndrome (IBS) sufferers and overweight adults [24][25][26], an anti-invasive function (increasing protection against bacterial pathogens). It significantly reduces pathology and colonization associated with food-borne salmonellosis. It also reduces the incidence, severity and duration of traveller’s diarrhea [27][28][29].
- the ability to interact directly with the IS improving barrier function in the gut. Its positive immunomodulatory effect was further demonstrated in overweight adults with metabolic syndrome, where it significantly increased gut immune parameters involved in the protection against pathogens, as well as reducing blood and faecal inflammatory markers [25].

2.3. Human Milk Oligossacharides

Prebiotics are present in human milk and they are called human milk oligossacharides (HMOs). Human milk and colostrum are composed of oligosaccharides (5 g/L to 23 g/L) containing a lactose-reducing end elongated with fucosylated and/or sialylated N-acetyllactosamine units. There are over 150 HMOs structures that vary in their size, charge, and sequence [30]. The most frequent HMOs are the neutral fucosylated and non-fucosylated oligosaccharides [31]. The amount and structure of these HMOs can be really different between women and is dependent upon the Secretor and Lewis blood group status (see Figure 2). A deficiency of α 1, 2-linked fucosylated oligosaccharides in human milk is linked to the mutations in the fucosyltransferase 2 (FUT2) secretor gene. HMOs give no direct nutritional value to the infant, and are minor absorbed across the intestinal wall [32]. Instead, it is suggested, that HMOs can play many other roles for the infant. They are preferred substrates for several species of gut bacteria and act as prebiotics, promoting the growth of beneficial intestinal flora and shaping the gut microbiome. Short-chain fatty acids (SCFA) induced by the gut microbiome fermentation of HMOs are critical for intestinal health [33]. They stimulate the growth of gut commensal bacteria along with giving nourishment for epithelial cells lining the gut. HMOs also directly modulate host-epithelial responses, favoring reduced binding of pathogens to the gut barrier. Intestinal microbiota composition varies between formula-fed and breastfed infants, maybe due to the lack of HMOs in infant formula milk [34]. HMOs act probably as decoy receptors, inhibiting the binding of enteric pathogens to prevent infection and subsequent illness. Furthermore, HMOs induce a selective advantage for colonization by favorable bacteria, thereby inhibiting the growth of pathogenic species.
Figure 2. Human milk oligosaccharide composition blueprint.
The HMO composition follows a basic blueprint shown in the center. HMOs contain five different monosaccharides in different numbers and linkages, namely glucose (blue circle), galactose (yellow circle), N-acetlylactosamine (blue square), fucose (red triangle), and sialic acid (purple diamond). All HMOs carry lactose at the reducing end. Lactose can be fucosylated or sialylated to induce the small HMOs 2′-fucosyllactose and 3-fucosyllactose or 3′-sialyllactose and 6′-sialyllactose, respectively (upper left corner). Alternatively, lactose can be elongated with type 1 or type 2 disaccharide units to form linear or branched HMOs (upper right corner). Elongated HMOs then can be sialylated (lower left corner) or fucosylated (lower right corner) or both sialylated and fucosylated (not shown). The HMOs in this figure are only a few relatively simple examples. So far, more than 150 different HMO structures have been characterized [35].

2.4. Prebiotics Mechanisms

Prebiotics can influence the host health by two distinct mechanisms: indirect (see Figure 3) or direct (see Figure 4). Indirectly, the prebiotics acts as a fermentable substrate for some specific commensal host bacteria. This nutrient source allows the growth of specific taxa and lead to a modulation of gut intestinal microbiota. The SCFAs released in the gut intestinal tract influence many molecular and cellular processes. Recently, new research explored the direct effect of prebiotics on several compartments and specifically on different patterns of cells (epithelial and immune cells).
Figure 3. Indirect effects of prebiotics. (A) The general mechanisms of SCFAs. The SCFAs are metabolites derived from the fermentation of prebiotics by the microbiota. They are consumed by the microbiota or released into the biological systems (blood, gut, lung, placenta). They can interact with the cells by three mechanisms. In the first mechanism, the GPRs which are receptors coupled to signaling pathways (AMP-activated protein kinase (AMP-K), mammalian target of rapamycin (mTOR), signal transducer and activator of transcription 3 (STAT3), mitogen-activated protein kinases (MAPKs), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)) are involved. The second mechanisms correspond to the diffusion channels (solute carrier family 16 member 1 (Slc) 16a1 and 5a8) that allow the SCFAs transport directly to cytoplasm and their potential interactions with pathways. By these two mechanisms, the signaling cascade is activated and can influence the transcription of genes by acetylation and deacetylation respectively via the histone acetyltransferases (HAT) and the histone deacetylases (HDAC) enzymes (epigenetic mechanisms). In the last mechanisms, there is a passive diffusion of SCFAs able to modulate directly enzymes (HDAC, HAT) involved in epigenetic processes. The modulation of genes expression by acetylation and deacetylation will have different consequences such as a modification of metabolism, cell cycle or microbial activity described in Figure 3B,C. (B) The specific impact of SCFAs on epithelial cells. SCFAs (butyrate, propionate) can interact with the G-protein coupled receptor (GPR)43 receptor and activates the mTOR/STAT3 pathway allowing the modulation of genes to increase the expression of antimicrobial peptides such as regenerating islet-derived protein 3 gamma (RegIIIγ) and β-defensins. SCFAs can directly increase the epithelial barrier function by stimulating O2 metabolism in intestinal epithelial cell lines. This mechanism results in the stabilization of the transcription factor hypoxia-inducible factor (HIF-1). SCFAs interact also with the GPR 41 (acetate, propionate) and GPR43 receptors to activate the extracellular signal-regulated kinases (ERK) 1/2 and MAPK signaling pathway. In this way, epithelial cells produce inflammatory chemokines and cytokines during the immune response to protect the organism against aggressions or infections. The consumption of SCFA also increases the secretion of the antimicrobial peptide by epithelial cells. (C) The specific impact of SCFAs on IS. SCFAs can be found in the bloodstream. They can interact with different immune cell subtypes. In a first step they can modify the hematopoeisis of dendritic cells (DC) precursors in the bone marrow and induce CD11c+ CD11b+ DCs in lung-draining lymph nodes. The cells CD11c+ CD11b+ DC have a lower capacity to activate the Th2 cell which results in the reduction of allergic asthma. SCFAs are also able to modify in vitro the functionality of FMS-like tyrosine kinase 3 ligand (Flt3L)-elicited splenic DCs: a lower ability to activate T cell and to transport antigen to the lymph node and a lower expression of chemokine (C-C motif) ligand 19 (CCL19) on their surface decreasing their ability to move in different sites. In the lungs SCFAs are able to inhibit the enzyme HDAC9 resulting in an increase of the forkhead box P3 (FoxP3) transcription factor and then an increase of the number and the activity of Treg. In the intestine the increase of retinoic acid-synthesizing (RALDH) enzyme activity during the consumption of SCFA, allows the conversion of vitamin A to the retinoic acid in tolerogenic DC CD103 +. Then, the retinoic acid acts directly on T cells and induces their differentiation into Treg.
Figure 4. Direct effects of prebiotics. (A) Direct effect of prebiotics on lung epithelial cells. Mannan prebiotic stimulates cell spreading and facilitates wound repair in damaged human bronchial epithelium, involving mannose receptors. Prebiotics also increases expression and activation of Krüppel-like factors (KLFs) inducing cell differentiation, survival, and proliferation. (B) Direct effect of prebiotics on skin epithelial cells. Prebiotics supplementation improved water retention and prevented erythema via the expression of CD44, metallopeptidase inhibitor 1 (TIMP)-1, and collagen type 1(Col1) improving the skin’s barrier properties. Prebiotics suppress overproductions of thymic stromal lymphopoietin (TSLP), substance P, IL-10, IL-4, and tumor necrosis factor (TNF)-a leading to reduced transepidermal water loss and skin dryness, prevention of keratin depletion, improvement of biophysical parameters of the epidermis, restoration of skin sebum levels, and limitation of bacterial infection. Prebiotics increase CD4+ Foxp3+ Treg in skin lymph nodes and prevent germline class-switching and IgE production. (C) Direct effect of prebiotics on gut epithelial cells. Prebiotics are Toll like receptor 4 (TLR4) ligands in IEC. Prebiotics induce a range of anti-inflammatory cytokines and reduce pro-inflammatory cytokines to inhibit gut inflammation. Prebiotics enhance galectin-9 expression correlated with reduced acute allergic skin reaction and mast cell degranulation and promoted Th1 and Treg responses. Prebiotics directly promoted barrier integrity to prevent pathogen-induced barrier disruptions involving the induction of protein kinase C (PKC). (D) Direct effect of prebiotics on immune cells. Prebiotics induce both the secretion of anti-inflammatory (IL-10) and pro-inflammatory (IL-1β and TNF-α) cytokines by blood monocytes due to the activation of the NF-ĸB pathway by the binding of TLR4. Prebiotics bind pathogen recognition receptor (PRRs) on the surface of DCs inducing IL-10 secretion and Treg cells. Prebiotics enhance the secretion of IL-10 and interferon-γ (IFN-γ) by CD4+ T cells and IgA.
Indirect Effects: The Short Chain Fatty Acids (see Figure 3)
Prebiotics are highly fermentable food ingredients. This feature promotes expansion and stimulates the implantation of some beneficial and bifidogenic bacteria. Indeed, it was shown that inulin consumption increases specifically and significantly the abundances of Bifidobacteria and Lactobacilli [17][36][37]. These gut microbiota modifications improve the host health, notably by inhibiting pathogen implantation in the gut. The increase of Bifidobacteria following prebiotic consumption was correlated with an increase of acetate production by Bifidobacteria, a decrease of the C. difficile pathogen population in the gut intestinal tract and an inhibition of pathogens translocation from the gut lumen to the blood [38][39]. The benefits of Bifidobacteria are well described in the literature, recent studies reported that new prebiotics (apple pectin and 1-kestose) efficiently stimulate the proliferation of Faecalibacterium prausnitzii known to possess an anti-inflammatory effect [40]. Indeed, the pectin promotes the expansion of Faecalibacterium prausnitzii, but also Eubacterium eligens DSM3376, which strongly improves in vitro the secretion of the anti-inflammatory cytokine IL-10 [41].
Prebiotics, by their ability to be fermented by bacteria, induce the production of SCFAs and thus act indirectly on health. SCFAs can be used in the gut intestinal tract by the microbiota for their own metabolism or released in the lumen. In the lumen, SCFAs can specifically interact with different cells such as intestinal epithelial cells (IEC) or innate/adaptive immune cells to modify various cellular processes as well as gene expression, differentiation, proliferation and apoptosis. SCFAs can activate G protein coupled receptors (GPRs), such as GPR41 or the free fatty acid receptor (Ffar)3 (acetate = propionate > butyrate), GPR43 or Ffar2 (butyrate = propionate > acetate), GPR109a (butyrate) and olfactory receptor (Olfr)-78 (propionate = acetate), to modulate cell development, function and survival [42]. They can also enter directly into the cells through transporters solute carrier family 16 member 1 (Slc) 16a1 and Slc5a8 or by passive diffusion to subsequently induce signaling pathways [43][44]. Signaling pathway induced by SCFAs-binding are mediated by various actors: protein kinases, such as the AMP-activated protein kinase (AMPK) [45], mitogen-activated protein kinases (MAPK) [46], mammalian target of rapamycin (mTOR), signal transducer and activator of transcription 3 (STAT3) [47] or nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) [48]. Either by downstream signaling pathways or directly, SCFAs modulate the function of several enzymes and transcription factors including histone acetyltransferase (HATs) or histone deacetylases (HDACs) [49]. Consequences of SCFAs-related genes transcription modification is well described: modification of cellular cycle, anti-microbial effects and metabolism (regulation of lipogenesis and lipolysis in the cytosol of hepatocytes and adipocytes, and action on central appetite regulation) [42]. 

2.5. Direct Effect of Prebiotics (see Figure 4)

2.6. IEC

It is well described that prebiotics modulate the gut microbiota leading to the decrease of intestinal inflammation. However, some studies suggest that oligosaccharides may exert an anti-inflammatory effect per se, also called “non-prebiotic effects”. When ingested, prebiotics enter the intestine and are in direct contact with the gut epithelial cells. Zenhom et al., have demonstrated in vitro the anti-inflammatory effect of prebiotics on enterocyte lineages, characterized by reduced IL-12 secretion in Caco-2 cells and gene expression of IL-12, p35, IL-8, and tumor necrosis factor α (TNF-α) such as the inhibition of the translocation of NF-ĸB factor to the nucleus [50]. This direct effect was the peroxisome proliferator-activated receptor gamma (PPARγ) and peptidoglycan recognition protein 3 (PGlyRP3) dependent. To assess direct effects of prebiotics, Ortega-González et al. also tested prebiotics in IEC in vitro [51]. Prebiotics promoted the production of growth-related oncogene (GROα), monocyte chemoattractant protein 1 (MCP-1), and macrophage inflammatory protein 2 (MIP2) with an efficacy that was 50%–80% that of lipopolysaccharides (LPS). Interestingly, the response was markedly decreased by Toll like receptor 4 (TLR4) gene knockdown highlighting that prebiotics are TLR4 ligands in IEC. This was confirmed in a study where treatment of epithelial cells with FOS regulated the expression of TLR-modulated genes including IL-10, TNF-α, CXCL-8 and CXCL-1 [52].
Moreover, dietary supplementation with a synbiotic (prebiotics short chain (sc) GOS/ long chain (lc) FOS in combination with probiotic Bifidobacterium breve M-16V) increases galectin-9 on the surface of IEC and circulating galectin-9 levels in mice and humans. These observations were correlated with a reduction of acute allergic skin reaction and mast cell degranulation [53]. Galectin-9 was shown to decrease mast cell degranulation and promotes Th1 and Treg responses. This research highlighted that a diet enriched with a synbiotic leads to the prevention of allergic symptoms [53].
To demonstrate the direct effects of prebiotics on the maintenance of epithelial barrier function, a study by Wu et al. investigated the application of prebiotics onto immortalized gut-derived epithelial cell lines and human intestinal organoids in the absence of microbes and in the context of epithelial injury caused by a non-invasive human enteric bacterial pathogen [54]. Prebiotics directly promoted barrier integrity to prevent pathogen-induced barrier disruptions involving the induction of select tight junction proteins through a protein kinase C (PKC) δ-dependent mechanism. Réquilé et al. confirmed the effects of prebiotics on the tight junction gene expression [55]. These results demonstrate a specific and direct host-nutrient interaction and elucidate a novel mechanism whereby prebiotics maintain gut homeostasis to protect the host against challenge by enteric pathogens or allergens.
Another study has highlighted the interactions between epithelial cells and DC regulation by prebiotics [56]. The addition of prebiotic alone in the culture medium of DC did not modify their secretion. However, the addition of the epithelial cell culture supernatant incubated with prebiotics on DC increases the IL-10/IL-12 secretion ratio by DC. This suggests that prebiotics induce tolerogenic DCs mediated by molecules secreted by epithelial cells. The interaction of prebiotics with epithelial cells and DCs led to changes in the polarization of T cells. Interestingly, the different fibers tested had differential effects on T-cell polarization. GOS, chicory inulin, wheat arabinoxylan, and barley -glucan increased the production of the Th1 cytokine IFN-γ, whereas the Th1 cytokine TNF-α was decreased by GOS and wheat arabinoxylan. Barley-glucan increased the Th1 cytokine IL-2 and suppressed Th2 responses. GOS was the only prebiotic able to promote functional Treg (increase of IL10 secretion). They conclude that direct modulation of the IECs-DCs crosstalk can induce a regulatory immune phenotype and selecting dietary fibers could be essential for future clinical trials on efficacy in allergy management.
In summary, these studies demonstrate that prebiotics modulate host cell signaling to promote epithelial barrier integrity by direct effects on the intestinal mucosa.

2.7. Skin Epithelial Cells

It has been shown in mice, that GOS supplementation prevented trans epidermal water loss and UV-induced erythema via dermal expression of cell adhesion and matrix formation markers CD44, metallopeptidase inhibitor 1 (TIMP)-1, and collagen type 1(Col1), thereby improving the skin’s barrier properties [57]. It has also been shown in an AD mouse model that skin inflammatory cell infiltrations (such as skin Th2-related cytokines, TSLP and IL-4) were significantly reduced by treatments with FOS [58]. Moreover, CD4+ Foxp3+ Treg cells were significantly increased in skin lymph nodes. Finally, also in a mouse model of AD, supplementation with prebiotics (Konjac glucomannan) inhibits a scratching behavior and skin inflammatory immune responses by preventing germline class-switching and IgE production [59]. Prebiotic dietary supplementation significantly suppressed eczematous skin lesions, dermal mastocytosis and eosinophilia. Concomitantly, cutaneous overproductions of substance P, IL-10, IL-4, and TNF-α were all inhibited [60].
The prebiotic effects on skin epithelial cells in humans were confirmed in a double-blind, randomized trial on adult healthy subjects divided into two groups, control and GOS oral supplementation for 12 weeks [61]. The authors reported that GOS supplementation was beneficial to the skin characterized by better corneometer values and reduced transepidermal water loss (TEWL). In addition, the differences in total and percentage of wrinkle areas between the two groups were statistically significant after 12 weeks of GOS treatment. Finally, GOS can also prevent keratin depletion caused by phenolic compounds. In another trial involving patients with skin damage due to diabetes, 4 weeks of daily application of emollient containing prebiotics improved biophysical parameters of the epidermis [62]. They observed a decrease of the TEWL and skin dryness, and the restoration of skin sebum levels. Normalization of skin pH was suggested as the beneficial mechanism through improved epidermal skin integrity and limitation of bacterial infection.
In conclusion, both oral supplementation and cutaneous application with prebiotics have an impact on the biophysical parameters of the epidermis, improving the skin’s barrier properties. Knowing that the skin is an important route for allergen sensitization in AD infants [63], it would be interesting to study the effect of prebiotics application on the skin in high-atopy-risk infants to potentially reduce the risk of allergen skin sensitization.

2.8. Lung Epithelial Cells

In asthmatic airways, repeated epithelial damage and repair occur and the disrupted epithelial barrier and epithelial dysfunction are crucial in the induction and maintenance of asthma symptoms. No current therapy directly targets this process. Michael et al. have shown that treatment with prebiotics (Mannan Derived from Saccharomyces cerevisiae) stimulated cell spreading and facilitates wound repair in human bronchial epithelium, involving mannose receptors [64]. Prebiotics also increased the expression and activation of Krüppel-like factors (KLFs) 4 and 5, key transcription factors for epithelial cell differentiation, survival, and proliferation.

2.9. Immune System

The intestinal IS, also called gut-associated lymphoid tissue (GALT), is a secondary lymphoid organ involved in the processing of antigens that interact with the gut mucosa and the diffusion of the immune response. Prebiotics can be absorbed through the intestinal barrier and may thus be in direct contact with circulating IS cells. Inulin and FOS induce the secretion of IL-10, IL-1β and TNF-α by blood monocytes [65]. This secretion is due to the activation of the NF-κB pathway by the binding of the TLR4. In contrast, FOS and inulin do not have a significant impact on cytokine secretion by T lymphocytes. Possible direct effects of prebiotics are thought to entail ligation of pathogen recognition receptors (PRRs) on the surface of intestine DCs [66]. These PRRs involved in prebiotics signaling include TLRs, C-type lectin receptors (CLRs), NOD-like receptors (NLRs), and galectins. On DC derived from human blood monocytes, GOS and FOS induce IL-10 secretion stimulated by TLR4 binding [67]. Increased secretion of IL-10 by DC leads to the induction of regulatory Foxp3+ T cells. However, Perdijk et al. have shown that HMOs (6′-SL and 2′-FL) and GOS do not alter DC differentiation or maturation of in vitro differentiated DC types [68]. It was also shown that prebiotics supplementation in rats acted at the level of GALT enhancing the production of IL-10 and IFN-γ by CD4+ T lymphocytes in Peyer’s patches as well as the production of IgA in the caecum, compared with controls [69]. Caecal IgA secretion was shown to be dependent on the degree of polymerization of prebiotics [70]. Another study on mice also showed that FOS supplementation increased the secretion of IFN-γ and IL-10 in CD4+ T cells derived from Peyer’s patches [71].

This entry is adapted from the peer-reviewed paper 10.3390/nu11081841

References

  1. Prescott, S.L. Early-life environmental determinants of allergic diseases and the wider pandemic of inflammatory noncommunicable diseases. J. Allergy Clin. Immunol. 2013, 131, 23–30.
  2. Pawankar, R.; Canonica, G.W.; Holgate, S.T.; Lockey, R. World Allergy Organization (WAO) white book on allergy; World Allergy Organization: Milwaukee, WI, USA, 2011.
  3. Chinthrajah, R.S.; Hernandez, J.D.; Boyd, S.D.; Galli, S.J.; Nadeau, K.C. Molecular and cellular mechanisms of food allergy and food tolerance. J. Allergy Clin. Immunol. 2016, 137, 984–997.
  4. Nylund, L.; Nermes, M.; Isolauri, E.; Salminen, S.; De Vos, W.M.; Satokari, R. Severity of atopic disease inversely correlates with intestinal microbiota diversity and butyrate-producing bacteria. Allergy Eur. J. Allergy Clin. Immunol. 2015, 70, 241–244.
  5. Werfel, T.; Allam, J.P.; Biedermann, T.; Eyerich, K.; Gilles, S.; Guttman-Yassky, E.; Hoetzenecker, W.; Knol, E.; Simon, H.U.; Wollenberg, A.; et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2016, 138, 336–349.
  6. West, C.E.; Jenmalm, M.C.; Prescott, S.L. The gut microbiota and its role in the development of allergic disease: A wider perspective. Clin. Exp. Allergy 2015, 45, 43–53.
  7. Chiu, C.Y.; Chan, Y.L.; Tsai, M.H.; Wang, C.J.; Chiang, M.H.; Chiu, C.C. Gut microbial dysbiosis is associated with allergen-specific IgE responses in young children with airway allergies. World Allergy Organ. J. 2019, 12, 1–12.
  8. Fieten, K.B.; Totté, J.E.E.; Levin, E.; Reyman, M.; Meijer, Y.; Knulst, A.; Schuren, F.; Pasmans, S.G.M.A. Fecal microbiome and food allergy in pediatric atopic dermatitis: A cross-sectional pilot study. Int. Arch. Allergy Immunol. 2018, 175, 77–84.
  9. Zimmermann, P.; Messina, N.; Mohn, W.W.; Finlay, B.B.; Curtis, N. Association between the intestinal microbiota and allergic sensitization, eczema, and asthma: A systematic review. J. Allergy Clin. Immunol. 2019, 143, 467–485.
  10. Demirci, M.; Tokman, H.; Uysa, H.; Demirvas, S.; Karakullukcu, A.; Saribas, S.; Cokugras, H.; Kocazeybey, B. Reduced Akkermansia muciniphila and Faecalibacterium prausnitzii levels in the gut microbiota of children with allergic asthma. Allergol. Immunopathol. 2019, 19, 1–10.
  11. Chassaing, B.; Vijay-kumar, M.; Gewirtz, A.T. How diet can impact gut microbiota to promote or endanger health. Curr. Opin. Gastroenterol. 2017, 33, 417–421.
  12. Tulic, M.K.; Hodder, M.; Forsberg, A.; McCarthy, S.; Richman, T.; D’Vaz, N.; Van Den Biggelaar, A.; Thornton, C.A.; Prescott, S.L. Differences in innate immune function between allergic and nonallergic children: New insights into immune ontogeny. J. Allergy Clin. Immunol. 2011, 127, 470–478.
  13. Tulic, M.K.; Andrews, D.; Crook, M.L.; Charles, A.; Tourigny, M.R.; Moqbel, R.; Prescott, S.L. Changes in thymic regulatory T-cell maturation from birth to puberty: Differences in atopic children. J. Allergy Clin. Immunol. 2012, 129, 199–206.
  14. Savage, J.; Johns, C.B. Food Allergy: Epidemiology and Natural History. Immunol Allergy Clin North. Am. 2015, 35, 45–59.
  15. Gollwitzer, E.S.; Marsland, B.J. Impact of Early-Life Exposures on Immune Maturation and Susceptibility to Disease. Trends Immunol. 2015, 36, 684–696.
  16. Renz, H.; Holt, P.G.; Inouye, M.; Logan, A.C.; Prescott, S.L.; Sly, P.D. An exposome perspective: Early-life events and immune development in a changing world. J. Allergy Clin. Immunol. 2017, 140, 24–40.
  17. Gibson, G.R.; Roberfroid, M.B. Dietary Modulation of the Human Colonie Microbiota: Introducing the Concept of Prebiotics. J. Nutr. 1995, 125, 1401–1412.
  18. Gibson, G.; Hutkins, R.; Sanders, M.E.; Prescott, S.L.; Reimer, R.A.; Salminen, S.J.; Scott, K.; Stanton, C.; Swanson, K.; Cani, P.; et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 491–502.
  19. Kaczmarczyk, M.M.; Miller, M.J.; Freund, G.G. The health benefits of dietary fiber: beyond the usual suspects of type 2 diabetes, cardiovascular disease and colon cancer. Metabolism 2013, 61, 1058–1066.
  20. Bindels, L.B.; Delzenne, N.M.; Cani, P.D.; Walter, J. Opinion: Towards a more comprehensive concept for prebiotics. Nat. Rev. Gastroenterol. Hepatol. 2015, 12, 303–310.
  21. Loo, J.V.; Coussement, P.; De Leenheer, L.; Hoebreg, H.; Smits, G. On the Presence of Inulin and Oligofructose as Natural Ingredients in the Western Diet. Crit. Rev. Food Sci. Nutr. 1995, 35, 525–552.
  22. Fernández, J.; Redondo-Blanco, S.; Miguélez, E.M.; Villar, C.J.; Clemente, A.; Lombó, F. Healthy effects of prebiotics and their metabolites against intestinal diseases and colorectal cancer. AIMS Microbiol. 2015, 1, 48–71.
  23. Depeint, F.; Tzortzis, G.; Vulevic, J.; I’anson, K.; Gibson, G.R. Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 41171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study. Am. J. Clin. Nutr. 2008, 87, 785–791.
  24. Vulevic, J.; Drakoularakou, A.; Yaqoob, P.; Tzortzis, G.; Gibson, G.R. Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers. Am. J. Clin. Nutr. 2008, 88, 1438–1446.
  25. Vulevic, J.; Juric, A.; Tzortzis, G.; Gibson, G.R. A Mixture of trans-Galactooligosaccharides Reduces Markers of Metabolic Syndrome and Modulates the Fecal Microbiota and Immune Function of Overweight Adults. J. Nutr. 2013, 143, 324–331.
  26. Silk, D.B.A.; Davis, A.; Vulevic, J.; Tzortzis, G.; Gibson, G.R. Clinical trial: The effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2009, 29, 508–518.
  27. Searle, L.E.J.; Best, A.; Nunez, A.; Salguero, F.J.; Johnson, L.; Weyer, U.; Dugdale, A.H.; Cooley, W.A.; Carter, B.; Jones, G.; et al. A mixture containing galactooligosaccharide, produced by the enzymic activity of bifidobacterium bifidum, reduces salmonella enterica serovar typhimurium infection in mice. J. Med. Microbiol. 2009, 58, 37–48.
  28. Searle, L.E.J.; Cooley, W.A.; Jones, G.; Nunez, A.; Crudgington, B.; Weyer, U.; Dugdale, A.H.; Tzortzis, G.; Collins, J.W.; Woodward, M.J.; et al. Purified galactooligosaccharide, derived from a mixture produced by the enzymic activity of Bifidobacterium bifidum, reduces Salmonella enterica serovar Typhimurium adhesion and invasion in vitro and in vivo. J. Med. Microbiol. 2010, 59, 1428–1439.
  29. Drakoularakou, A.; Tzortzis, G.; Rastall, R.A.; Gibson, G.R. A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel galacto-oligosaccharide mixture in reducing travellers’ diarrhoea. Eur. J. Clin. Nutr. 2010, 64, 146–152.
  30. Zivkovic, A.M.; German, J.B.; Lebrilla, C.B.; Mills, D.A. Human milk glycobiome and its impact on the infant gastrointestinal microbiota. Proc. Natl. Acad. Sci. USA 2010, 108, 4653–4658.
  31. Doherty, A.M.; Lodge, C.J.; Dharmage, S.C.; Dai, X.; Bode, L.; Lowe, A.J. Human Milk Oligosaccharides and Associations with immune-mediated disease and infection in childhood: A systematic review. Front. Pediatr. 2018, 6, 1–8.
  32. Kunz, C.; Rudloff, S. Compositional analysis and metabolism of human milk oligosaccharides in infants. Nestle Nutr. Inst. Workshop Ser. 2017, 88, 137–147.
  33. Donovan, S.M.; Comstock, S.S. Human milk oligosaccharides influence neonatal mucosal and systemic immunity. Ann. Nutr. Metab. 2016, 69, 42–51.
  34. Wang, M.; Li, M.; Wu, S.; Lebrilla, C.B.; Chapkin, R.S.; Ivanov, I.; Donovan, S.M. Fecal microbiota composition of breast-fed infants is correlated with human milk oligosaccharides consumed. J. Pediatr. Gastroenterol. Nutr. 2015, 60, 825–833.
  35. Triantis, V.; Bode, L.; van Neerven, R.J.J. Immunological Effects of Human Milk Oligosaccharides. Front. Pediatr. 2018, 6, 1–14.
  36. Slavin, J. Fiber and prebiotics: Mechanisms and health benefits. Nutrients 2013, 5, 1417–1435.
  37. Vandeputte, D.; Falony, G.; Vieira-Silva, S.; Wang, J.; Sailer, M.; Theis, S.; Verbeke, K.; Raes, J. Prebiotic inulin-type fructans induce specific changes in the human gut microbiota. Gut 2017, 66, 1968–1974.
  38. Hopkins, M.J.; Macfarlane, G.T. Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro. Appl. Environ. Microbiol. 2003, 69, 1920–1927.
  39. Fukuda, S.; Toh, H.; Hase, K.; Oshima, K.; Nakanishi, Y.; Yoshimura, K.; Tobe, T.; Clarke, J.M.; Topping, D.L.; Suzuki, T.; et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011, 469, 543–549.
  40. Tochio, T.; Kadota, Y.; Tanaka, T.; Koga, Y. 1-Kestose, the smallest fructooligosaccharide component, which efficiently stimulates faecalibacterium prausnitzii as well as bifidobacteria in humans. Foods 2018, 7, 140.
  41. Chung, W.S.F.; Meijerink, M.; Zeuner, B.; Holck, J.; Louis, P.; Meyer, A.S.; Wells, J.M.; Flint, H.J.; Duncan, S.H. Prebiotic potential of pectin and pectic oligosaccharides to promote anti-inflammatory commensal bacteria in the human colon. FEMS Microbiol. Ecol. 2017, 93, 1–9.
  42. Corrêa-Oliveira, R.; Fachi, J.L.; Vieira, A.; Sato, F.T.; Vinolo, M.A.R. Regulation of immune cell function by short-chain fatty acids. Clin. Transl. Immunol. 2016, 5, 1–8.
  43. Hiroki, T.; Tohru, Y.; Ryo, I.; Kazunari, U.; Kumiko, T.; Junko, N. The cellular expression of SMCT2 and its comparison with other transporters for monocarboxylates in the mouse digestive tract. Biomed. Res. 2010, 31, 239–249.
  44. Takebe, J.; Nio, J.N.; Orimatsu, M.M.; Araki, S.K.; Uwahara, A.K.; Ato, I.K. Histochemical demonstration of a Na+ -coupled transporter for short-chain fatty acids (Slc5a8) in the intestine and kidney of the mouse. Biomed. Res. 2005, 26, 213–221.
  45. Den Besten, G.; van Eunen, K.; Groen, A.K.; Venema, K.; Reijngoud, D.-J.; Bakker, B.M. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 2013, 54, 2325–2340.
  46. Jung, T.H.; Park, J.H.; Jeon, W.M.; Han, K.S. Butyrate modulates bacterial adherence on LS174T human colorectal cells by stimulating mucin secretion and MAPK signaling pathway. Nutr. Res. Pract. 2015, 9, 343–349.
  47. Zhao, Y.; Chen, F.; Wu, W.; Sun, M.; Bilotta, A.J.; Yao, S.; Xiao, Y.; Huang, X.; Eaves-Pyles, T.D.; Golovko, G.; et al. GPR43 mediates microbiota metabolite SCFA regulation of antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR and STAT3. Mucosal Immunol. 2018, 11, 752–762.
  48. Li, M.; Van Esch, B.C.A.M.; Henricks, P.A.J.; Garssen, J.; Folkerts, G. Time and Concentration Dependent Effects of Short Chain Fatty Acids on Lipopolysaccharide- or Tumor Necrosis Factor α -Induced Endothelial Activation. Front. Pharmacol. 2018, 9, 1–12.
  49. Li, M.; Van Esch, B.C.A.M.; Wagenaar, G.T.M.; Garssen, J.; Folkerts, G.; Henricks, P.A.J. Pro- and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells. Eur. J. Pharmacol. 2018, 831, 52–59.
  50. Zenhom, M.; Hyder, A.; de Vrese, M.; Heller, K.J.; Roeder, T.; Schrezenmeir, J. Prebiotic Oligosaccharides Reduce Proinflammatory Cytokines in Intestinal Caco-2 Cells via Activation of PPAR and Peptidoglycan Recognition Protein 3. J. Nutr. 2011, 141, 971–977.
  51. Ortega-González, M.; Ocón, B.; Romero-Calvo, I.; Anzola, A.; Guadix, E.; Zarzuelo, A.; Suárez, M.D.; Sánchez de Medina, F.; Martínez-Augustin, O. Nondigestible oligosaccharides exert nonprebiotic effects on intestinal epithelial cells enhancing the immune response via activation of TLR4-NFκB. Mol. Nutr. Food Res. 2014, 58, 384–393.
  52. Johnson-Henry, K.C.; Pinnell, L.J.; Waskow, A.M.; Irrazabal, T.; Martin, A.; Hausner, M.; Sherman, P.M. Short-Chain Fructo-oligosaccharide and Inulin Modulate Inflammatory Responses and Microbial Communities in Caco2-bbe Cells and in a Mouse Model of Intestinal Injury. J. Nutr. 2014, 144, 1725–1733.
  53. De Kivit, S.; Saeland, E.; Kraneveld, A.D.; Van De Kant, H.J.G.; Schouten, B.; Van Esch, B.C.A.M.; Knol, J.; Sprikkelman, A.B.; Van Der Aa, L.B.; Knippels, L.M.J.; et al. Galectin-9 induced by dietary synbiotics is involved in suppression of allergic symptoms in mice and humans. Allergy 2012, 67, 343–352.
  54. Wu, R.Y.; Abdullah, M.; Määttänen, P.; Pilar, A.V.C.; Scruten, E.; Johnson-Henry, K.C.; Napper, S.; O’Brien, C.; Jones, N.L.; Sherman, P.M. Protein kinase C δ signaling is required for dietary prebiotic-induced strengthening of intestinal epithelial barrier function. Sci. Rep. 2017, 7, 1–10.
  55. Réquilé, M.; Gonzàlez Alvarez, D.O.; Delanaud, S.; Rhazi, L.; Bach, V.; Depeint, F.; Khorsi-Cauet, H. Use of a combination of in vitro models to investigate the impact of chlorpyrifos and inulin on the intestinal microbiota and the permeability of the intestinal mucosa. Environ. Sci. Pollut. Res. 2018, 25, 1–12.
  56. Bermudez-Brito, M.; Sahasrabudhe, N.M.; Rösch, C.; Schols, H.A.; Faas, M.M.; De Vos, P. The impact of dietary fibers on dendritic cell responses in vitro is dependent on the differential effects of the fibers on intestinal epithelial cells. Mol. Nutr. Food Res. 2015, 59, 698–710.
  57. Hong, K.B.; Jeong, M.; Han, K.S.; Hwan Kim, J.; Park, Y.; Suh, H.J. Photoprotective effects of galacto-oligosaccharide and/or Bifidobacterium longum supplementation against skin damage induced by ultraviolet irradiation in hairless mice. Int. J. Food Sci. Nutr. 2015, 66, 923–930.
  58. Kim, H.J.; Lee, S.H.; Go, H.N.; Ahn, J.R.; Kim, H.J.; Hong, S.J. Effects of kestose on gut mucosal immunity in an atopic dermatitis mouse model. J. Dermatol. Sci. 2018, 89, 27–32.
  59. Suzuki, H.; Oomizu, S.; Yanase, Y.; Onishi, N.; Uchida, K.; Mihara, S.; Ono, K.; Kameyoshi, Y.; Hide, M. Hydrolyzed Konjac glucomannan suppresses IgE production in mice B cells. Int. Arch. Allergy Immunol. 2010, 152, 122–130.
  60. Onishi, N.; Kawamoto, S.; Ueda, K.; Yamanaka, Y.; Katayama, A.; Suzuki, H.; Aki, T.; Hashimoto, K.; Hide, M.; Ono, K. Dietary Pulverized Konjac Glucomannan Prevents the Development of Allergic Rhinitis-Like Symptoms and IgE Response in Mice. Biosci. Biotechnol. Biochem. 2007, 71, 2551–2556.
  61. Hong, Y.H.; Chang, U.J.; Kim, Y.S.; Jung, E.Y.; Suh, H.J. Dietary galacto-oligosaccharides improve skin health: A randomized double blind clinical trial. Asia Pac. J. Clin. Nutr. 2017, 26, 613–618.
  62. Narbutt, J.; Bednarski, I.A.; Lesiak, A. The effect of an emollient with benfothiamine and Biolin prebiotic on the improvement of epidermal skin function. Postep. Dermatologii i Alergol. 2016, 33, 224–231.
  63. Smith, A.R.; Knaysi, G.; Wilson, J.M.; Wisniewski, J.A. The Skin as a Route of Allergen Exposure: Part I. Immune Components. Curr Allergy Asthma Rep. 2017, 17, 1–18.
  64. Michael, C.F.; Waters, C.M.; LeMessurier, K.S.; Samarasinghe, A.E.; Song, C.Y.; Malik, K.U.; Lew, D.B. Airway Epithelial Repair by a Prebiotic Mannan Derived from Saccharomyces cerevisiae. J. Immunol. Res. 2017, 2017, 1–7.
  65. Capitan-Canadas, F.; Ortega-Gonzalez, M.; Guadix, E.; Zarzuelo, A.; Suarez, M.D.; de Medina, F.S.; Martinez-Augustin, O. Prebiotic oligosaccharides directly modulate proinflammatory cytokine production in monocytes via activation of TLR4. Mol. Nutr. Food Res. 2014, 58, 1098–1110.
  66. De Kivit, S.; Kraneveld, A.D.; Garssen, J.; Willemsen, L.E.M. Glycan recognition at the interface of the intestinal immune system: Target for immune modulation via dietary components. Eur. J. Pharmacol. 2011, 668, 124–132.
  67. Lehmann, S.; Hiller, J.; Van Bergenhenegouwen, J.; Knippels, L.M.J.; Garssen, J.; Traidl-Hoffmann, C. In vitro evidence for immune-modulatory properties of non-digestible oligosaccharides: Direct effect on human monocyte derived dendritic cells. PLoS ONE 2015, 10, 1–15.
  68. Perdijk, O.; Joost van Neerven, R.J.; Van den Brink, E.; Savelkoul, H.F.J.; Brugman, S. The oligosaccharides 6′-sialyllactose, 2′-fucosyllactose or galactooligosaccharides do not directly modulate human dendritic cell differentiation or maturation. PLoS One 2018, 13, 1–15.
  69. Roller, M.; Rechkemmer, G.; Watzl, B. Prebiotic Inulin Enriched with Oligofructose in Combination with the Probiotics Lactobacillus rhamnosus and Bifidobacterium lactis Modulates Intestinal Immune Functions in Rats. J. Nutr. 2018, 134, 153–156.
  70. Ito, H.; Takemura, N.; Sonoyama, K.; Kawagishi, H.; Topping, D.L.; Conlon, M.A.; Morita, T. Degree of polymerization of inulin-type fructans differentially affects number of lactic acid bacteria, intestinal immune functions, and immunoglobulin a secretion in the rat cecum. J. Agric. Food Chem. 2011, 59, 5771–5778.
  71. Takahashi, T.; Nakagawa, E.; Nara, T.; Yajima, T.; Kuwata, T. Effects of Orally Ingested Bifidobacterium longum on the Mucosal IgA Response of Mice to Dietary Antigens. Biosci. Biotechnol. Biochem. 2005, 62, 10–15.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback